Author, year Study type Study period Follow-up Country Population Bismuth-containing quadruple therapy Control
n (M/F) Age Drug Therapy time n (M/F) Age Drug Therapy time
Calvet 1998 RCT 1994.07-1996.02 12 months Spain Patients with PU and H. pyloripositive 42 (35/7) 51.9±15.51 O 40 mg b.i.d.;
A 2500mg once daily;
M 500 mg t.i.d.;
B 360 mg t.i.d.
2 days 39 (27/12) 52.5±13.9 O 20 mg b.i.d.;
A 1000 mg t.i.d.;
M 500 mg t.i.d.
14 days
Calvet 2002 RCT 1999.04-2001.01 6 months Spain Patients diagnosed of PU and H. pylori 168 (120/48) 52.6±17.4 O 20 mg b.i.d.;
T 500 mg t.i.d.;
M 500 mg t.i.d.;
B: 120 mg t.i.d.
7 days 171 (117/54) 51.5±15.9 O 20 mg b.i.d.;
A 1000 mg t.i.d.;
C 500 mg t.i.d.
7 days
Kim 2013 RCT 2003-2010 12 months Korea Patients with persistent H. pylori infection 59 (35/24) 56.1±9.3 E 20 mg b.i.d.;
M 500 mg t.i.d.;
T 500 mg q.i.d.;
B 300 mg q.i.d.;
14 days 116 (69/47) 56.8±9.5 M 400 mg q.i.d.;
E 20 mg b.i.d.;
A 1000 mg b.i.d.
14 days
Lara 2003 RCT 1998.08-2000.12 NR USA Patients with dyspepsia and H. pylori infection 80 (36/44) 46±12 M 500 mg q.i.d.;
A 2000 mg q.i.d.;
Lan 30*2mg once;
B 262*2 mg q.i.d.
7 day 80 (33/47) 53±16 C 500 mg b.i.d.;
A 500*2 mg b.i.d.;
Lan 30 mg b.i.d.
7 days
Liao 2013 RCT 2012 NR China Patients diagnosed of H. pylori positive 80 (43/37) 46.7 (23-78)2 Lan 30 mg b.i.d.;
A 1000 mg b.i.d.;
Lev 500 mg once;
B 220 mg b.i.d.
14 days 81 (46/35) 48.9 (23-75) Lan 30 mg b.i.d.;
A 1000 mg b.i.d.;
Lev 500 mg once
14 days
Momeni 2014 Double-blind RCT NR NR Iran Patients diagnosed of PU and H. pyloripositive 30 (13/17) 40.8±15.5 O 20 mg b.i.d.;
A 1000 mg b.i.d.;
M 500 mg b.i.d.;
B 262*2 mg b.i.d.
NR 30 (14/16) 42.2 ± 15.8 M 500 mg b.i.d.;
A 1000 mg b.i.d.;
O 20 mg b.i.d.;
licorice 380 mg b.i.d.
NR
Pai 2003 RCT NR NR India Patients with H. pylori infection 33 (32/1) 37.5 (18-64) Lan 30 mg b.i.d.;
M 400 mg t.i.d.;
T 500 mg q.i.d.;
B 120 mg q.i.d.
10 days 35 (32/3) 41.5 (19-69) Lan 30 mg b.i.d.;
A 500 mg q.i.d.;
C 500 mg b.i.d.
10 days
Raoufi 2014 RCT 2012.07-2012.12 6 months Iran Patient with persistent dispepsia 55 NR F 100 mg q.i.d.;
T 250 mg q.i.d.;
O 20 mg b.i.d.;
B 120 mg q.i.d.
14 days 55 NR O 20 mg b.i.d.;
A 1000 mg b.i.d.;
C 500 mg b.i.d.
14 days
Seyedmajidi 2013 Double-blind RCT 2007.03-2011.09 NR Iran Patients diagnosed of H. pylori positive 110 (40/60) 44.0±3.2 O 20 mg b.i.d.;
A 1000 mg b.i.d.;
M 500 mg b.i.d.;
B 240 mg b.i.d.
14 days 98 (55/43) 43.3±3.3 O 20 mg b.i.d.;
A 1000 mg b.i.d.;
C 500 mg b.i.d.
14 days
Xie 2014 Multi-center RCT 2010.01-2011.06 NR China Patients with H. pyloriinfection 180 (118/62) 39.6±13.6 R 10 mg b.i.d.;
A 1000 mg b.i.d.;
F 100 mg b.i.d.;
B 220 mg b.i,d,
7 days 180 (105/75) 41.4±12.6 R 10 mg b.i.d.;
A 1000 mg b.i.d.;
F 100 mg b.i.d.
7 days
Abbreviations: RCT: randomized controlled trial; M/F: male/female; PU: peptic ulcer; b.i.d.: bis in die (=twice a day); t.i.d.: ter in die (=three times a day); q.i.d.: quater in diē (=four times a day); B: bismuth; O: omeprazole; A: amoxicillin; M: metronidazole; T: tetracycline; C: clarithromycin; E: esomeprazole; Lan: lansoprazole; Lev: levofloxacin; F: furazolidone; R: rabeprazole; NR: not reported.
1 Data were given as mean±SD; 2 Data were given as mean (range).
Table 1: Characteristics of the selected studies.